MarketPulse
D

$DXCM

11 articles found
9 positive
0 negative
2 neutral
Investing.comInvesting.com··Nathan Reiff

DexCom Surges on Strong Earnings, Analyst Confidence as CGM Market Expands

DexCom beats Q1 earnings with $1.2B revenue, boasts 20 Buy ratings. New products and margin expansion drive 40% upside potential.
MDTDXCMmanufacturing expansionanalyst-ratings
Investing.comInvesting.com··David Wagner

Nine Stocks Poised to Defy 'Sell in May' as Market Hits New Highs

Record earnings beats and 27% growth challenge the 'Sell in May' strategy in 2026, with selective stock opportunities offering upside potential despite geopolitical risks.
DXCMRMDstock markethealthcare stocks
BenzingaBenzinga··Usa News Group

Medtech Giants Race to Acquire AI Diagnostics as Hospital Demand Surges

Medtech giants aggressively acquiring AI diagnostic platforms as hospital adoption surges. $2.20B market projected by 2026 with 34.8% growth through 2033.
MDTDHRDXCMPROFAI diagnosticsclinical validation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CGM Market Booming in Middle East and Africa: 168% Growth Projected by 2034

Middle East and Africa CGM market projected to reach USD 855.30 million by 2034 from USD 320.44 million in 2025, growing at 11.53% CAGR.
MDTABTDXCMSENShealthcare technologymarket forecast
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom's Glucose Monitors Poised to Win Regardless of Weight-Loss Drug Champion

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.
LLYNVODXCMweight loss drugsnetwork effects
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott vs. Dexcom: Which CGM Leader Offers Better Value in 2024?

Abbott offers diversified healthcare exposure with dividend income; Dexcom provides pure CGM growth but faces GLP-1 drug competition and concentration risk.
ABTDXCMdividend stockshealthcare stocks
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Sotera Health Shares Surge 18% as Major Investor Trims $37M Stake

MIG Capital trims $37.4M Sotera Health stake while maintaining significant position. Company posts record profits, 20-year revenue growth streak amid 18% annual share price gain.
METAMSFTDXCMSHCCELHportfolio rebalancingrevenue growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Surgical Robots and Glucose Monitors Positioned for Decade-Long Growth Despite Competition

Intuitive Surgical and DexCom positioned for long-term growth despite near-term competition, driven by aging populations and untapped market opportunities.
MDTDXCMISRGlong-term investinggrowth stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.
DXCMhealthcare stocksmedical devices
BenzingaBenzinga··Piero Cingari

Market Rally Broadens as Inflation Data Bolsters Rate-Cut Outlook

U.S. markets rally on softer inflation data boosting rate-cut expectations. Small-cap stocks, commodities, and growth sectors lead as investors bet on lower borrowing costs ahead.
DIADKNGCOINABNBQQQM+12earningsinflation